Work

Amikacin Dosing Analysis in Sepsis Treatment: A Pharmacokinetic Study Based on Therapeutic Drug Monitoring

Year: 2024

Type: article

Abstract: Objectives: The primary purpose of this research was to evaluate the loading dose and maintenance dose of amikacin in the treatment of sepsis from intensive care unit (ICU) patients from May to July 2023 at the dr. Ramelan Naval Central Hospital in Indonesia. The analysis focus on the use of therapeutic drug monitoring (TDM) results to improve efficacy and safety of amikacin therapy. Material and Methods: A total of 8 sepsis patients received amikacin for 5 days. The loading dose was administered regardless of the renal function and was calculated of 7.5mg / kg body weight, administered intravenously as a bolus. The subsequent maintenance dose was delivered 4 hours following the loading dose at 15mg / kg body weight by an intermittent drip for 1 hour. The TDM measurement was conducted twice on the third day, with sampling conducted at 1.5 and 4 hours following the administration of the third amikacin maintenance dose. Results: The TDM results revealed that the amikacin t½ elpatients demonstrated Cpmax/MIC indices exceeding 8, while three patients exhibited AUC0-24h/MIC indices surpassing 75. The data showed variabilities in pharmacokinetic characteristics of amikacin in the sepsis patients due to comorbidities specifically patient’s creatinine clearance. Conlusion: The dose administered at efficacious doses attaining the desired PK/PD target while minimizing the risk of toxicity The findings of pharmacokinetic parameters on septis patient in Indonesia give valuable insights into the potential of amikacin therapy to enhance the possibility of achieving an effective treatment.

Source: Journal of research in pharmaceutical science.

DOI: 10.35629/2995-10081220